Evidence map›Paper›PMID 35304657›Full record

ArticleJournal of computer-aided molecular design2022

Evolution of Support Vector Machine and Regression Modeling in Chemoinformatics and Drug Discovery.

Raquel Rodríguez-Pérez, Jürgen Bajorath

Open access · hybridAbstract read
In one paragraph

Article in Journal of computer-aided molecular design, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
29.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 211 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Raquel Rodríguez-PérezDepartment of Life Science Informatics, B-IT, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität, Friedrich-Hirzebruch-Allee 6, D-53115, Bonn, Germany.
Jürgen BajorathDepartment of Life Science Informatics, B-IT, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität, Friedrich-Hirzebruch-Allee 6, D-53115, Bonn, Germany. bajorath@bit.uni-bonn.de.ORCID 0000-0002-0557-5714
Novartis (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The support vector machine (SVM) algorithm is one of the most widely used machine learning (ML) methods for predicting active compounds and molecular properties. In chemoinformatics and drug discovery, SVM has been a state-of-the-art ML approach for more than a decade. A unique attribute of SVM is that it operates in feature spaces of increasing dimensionality. Hence, SVM conceptually departs from the paradigm of low dimensionality that applies to many other methods for chemical space navigation. The SVM approach is applicable to compound classification, and ranking, multi-class predictions, and -in algorithmically modified form- regression modeling. In the emerging era of deep learning (DL), SVM retains its relevance as one of the premier ML methods in chemoinformatics, for reasons discussed herein. We describe the SVM methodology including strengths and weaknesses and discuss selected applications that have contributed to the evolution of SVM as a premier approach for compound classification, property predictions, and virtual compound screening.

Indexed as

CheminformaticsSupport Vector MachineAlgorithmsDrug DiscoveryCompound classificationMachine learningProperty predictionRegressionSupport vector machines

Identifiers

PMID35304657
PMCPMC9325859
OpenAlexW4220753559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.